Towards a European production of stable isotopes for novel nuclear medicine therapies (SAMIRA/ERVI)

This grant supports the development of European Union production capabilities for stable isotopes essential to the manufacture of radionuclides used in novel nuclear medicine therapies. It aims to strengthen the resilience and security of the EU's medical radioisotope supply chain by securing access to source materials, reducing dependence on third countries (particularly Russia), and enhancing industrial-scale production. The funding leverages the expertise of nuclear scientists, physicists, and engineers to optimise processes for EU-based stable isotope production, with a major focus on medical uses relating to cancer and other serious diseases. The initiative aligns with Europe’s Beating Cancer Plan and the Strategic Agenda for Medical Ionising Radiation Applications (SAMIRA), and fosters partnerships with industry, policymakers, and healthcare professionals.

Check your compatibility

Agency	HORIZON (EU)
Region	EU
Country	N/A
Legal form	Company, NGO, Government organization, Other
Start date	23 Apr 2026
End date	15 Sep 2026
Max funding	2,000,000 EUR per grant (Innovation Actions, topic code 114605)
Budget	2026: 1,000,000 EUR 2027: 1,000,000 EUR
Coverage	Eligible costs covered as lump sum contributions according to Horizon Europe rules.

Grant application conditions

Admissibility	Proposal must follow the page limits and layout described in Annex A and Annex E of the Horizon Europe Work Programme General Annexes.
Eligible Countries	EU Member States and countries specified in Annex B of the Work Programme General Annexes. Some non-EU/non-Associated Countries may be eligible if specific provisions are made.
Consortium Participation	The Joint Research Centre (JRC) may participate as a consortium member. The Commission recommends using JRC’s services where appropriate.
Financial and Operational Capacity	Applicants must meet financial and operational capacity requirements described in Annex C of the Work Programme General Annexes.
Legal and Financial Set-up	Eligible costs take the form of a lump sum as defined in the relevant Horizon Europe legal documents.
Technology Readiness Level	Activities are expected to focus on TRL 5 to 7 (indicative, not mandatory).
Focus	Projects should aim for closer-to-market activities (including prototyping, testing, piloting, industrial scale-up). Limited R&D activities permitted.
Stakeholder Engagement	Applicants should foster partnerships with industry, policymakers, and healthcare professionals, and actively engage stakeholders across the nuclear medicine value chain.
Documentation	https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-EURATOM-LS-2026-01-05

Eligible expenses

Evaluation criteria

Business exclusions

Reporting

Application process

Application requirements